Eosinophilic Granulomatosis With Polyangiitis: A Real‐World Study of Biologics and Sinus Surgery Use for Managing Nasal Polyposis

Multidisciplinary multi-modality treatment with biologics and ESS appeared to be the mainstay of controlling NP in EGPA. Mepolizumab was the most frequently used biologic. Dual biologic therapy was necessary in 10% of patients. Overall, 71 of 80 (88.75%) patients had ESS, with almost half the study population (47.5%) undergoing ESS after initiating biologic treatment.